Fuan Pharmaceutical Group Co (300194) - Total Assets
Based on the latest financial reports, Fuan Pharmaceutical Group Co (300194) holds total assets worth CN¥5.97 Billion CNY (≈ $873.22 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Fuan Pharmaceutical Group Co net assets for net asset value and shareholders' equity analysis.
Fuan Pharmaceutical Group Co - Total Assets Trend (2007–2024)
This chart illustrates how Fuan Pharmaceutical Group Co's total assets have evolved over time, based on quarterly financial data.
Fuan Pharmaceutical Group Co - Asset Composition Analysis
Current Asset Composition (December 2024)
Fuan Pharmaceutical Group Co's total assets of CN¥5.97 Billion consist of 34.6% current assets and 65.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 14.2% |
| Accounts Receivable | CN¥272.01 Million | 4.6% |
| Inventory | CN¥850.97 Million | 14.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥544.81 Million | 9.1% |
| Goodwill | CN¥261.18 Million | 4.4% |
Asset Composition Trend (2007–2024)
This chart illustrates how Fuan Pharmaceutical Group Co's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Fuan Pharmaceutical Group Co worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Fuan Pharmaceutical Group Co's current assets represent 34.6% of total assets in 2024, a decrease from 45.1% in 2007.
- Cash Position: Cash and equivalents constituted 14.2% of total assets in 2024, up from 7.7% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, an increase from 8.0% in 2007.
- Asset Diversification: The largest asset category is inventory at 14.2% of total assets.
Fuan Pharmaceutical Group Co Competitors by Total Assets
Key competitors of Fuan Pharmaceutical Group Co based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.34 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥15.32 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
Fuan Pharmaceutical Group Co - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.18 | 1.66 | 1.84 |
| Quick Ratio | 1.46 | 1.06 | 1.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.11 Billion | CN¥860.05 Million | CN¥887.77 Million |
Fuan Pharmaceutical Group Co - Advanced Valuation Insights
This section examines the relationship between Fuan Pharmaceutical Group Co's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.17 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | 0.0% |
| Total Assets | CN¥5.98 Billion |
| Market Capitalization | $719.00 Million USD |
Valuation Analysis
Below Book Valuation: The market values Fuan Pharmaceutical Group Co's assets below their book value (0.12x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Fuan Pharmaceutical Group Co's assets decreased by 0.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Fuan Pharmaceutical Group Co (2007–2024)
The table below shows the annual total assets of Fuan Pharmaceutical Group Co from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.98 Billion ≈ $874.85 Million |
+0.04% |
| 2023-12-31 | CN¥5.98 Billion ≈ $874.47 Million |
+1.67% |
| 2022-12-31 | CN¥5.88 Billion ≈ $860.13 Million |
+3.01% |
| 2021-12-31 | CN¥5.71 Billion ≈ $835.03 Million |
-4.46% |
| 2020-12-31 | CN¥5.97 Billion ≈ $874.01 Million |
+26.12% |
| 2019-12-31 | CN¥4.74 Billion ≈ $693.02 Million |
+10.33% |
| 2018-12-31 | CN¥4.29 Billion ≈ $628.14 Million |
-8.45% |
| 2017-12-31 | CN¥4.69 Billion ≈ $686.12 Million |
+6.62% |
| 2016-12-31 | CN¥4.40 Billion ≈ $643.51 Million |
+77.39% |
| 2015-12-31 | CN¥2.48 Billion ≈ $362.77 Million |
+35.31% |
| 2014-12-31 | CN¥1.83 Billion ≈ $268.11 Million |
-1.67% |
| 2013-12-31 | CN¥1.86 Billion ≈ $272.67 Million |
+3.25% |
| 2012-12-31 | CN¥1.80 Billion ≈ $264.10 Million |
-0.68% |
| 2011-12-31 | CN¥1.82 Billion ≈ $265.90 Million |
+424.97% |
| 2010-12-31 | CN¥346.14 Million ≈ $50.65 Million |
+26.50% |
| 2009-12-31 | CN¥273.62 Million ≈ $40.04 Million |
+35.06% |
| 2008-12-31 | CN¥202.59 Million ≈ $29.64 Million |
+150.45% |
| 2007-12-31 | CN¥80.89 Million ≈ $11.84 Million |
-- |
About Fuan Pharmaceutical Group Co
Fuan Pharmaceutical (Group) Co., Ltd., together with its subsidiaries, research and develops, produces, and sells chemical drugs in the People's Republic of China. It offers APIs; intermediates; and FFPs, such as anti-tumor, generic drugs, antibiotics and oral, as well as freeze-drying preparation for injection. The company was formerly known as Chongqing Fuan Pharmaceutical (Group) Co., Ltd. and… Read more